Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
5.00
-0.38 (-7.06%)
At close: Mar 28, 2025, 4:00 PM
5.01
+0.01 (0.15%)
After-hours: Mar 28, 2025, 7:56 PM EDT
Jaguar Health Revenue
Jaguar Health had revenue of $3.11M in the quarter ending September 30, 2024, with 10.49% growth. This brings the company's revenue in the last twelve months to $10.48M, down -2.25% year-over-year. In the year 2023, Jaguar Health had annual revenue of $9.76M, down -18.36%.
Revenue (ttm)
$10.48M
Revenue Growth
-2.25%
P/S Ratio
0.09
Revenue / Employee
$213,878
Employees
49
Market Cap
2.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9.76M | -2.20M | -18.36% |
| Dec 31, 2022 | 11.96M | 7.62M | 175.80% |
| Dec 31, 2021 | 4.34M | -5.05M | -53.81% |
| Dec 31, 2020 | 9.39M | 3.61M | 62.51% |
| Dec 31, 2019 | 5.78M | 1.36M | 30.77% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2007 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
JAGX News
- 2 days ago - 83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey - Accesswire
- 3 days ago - Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study - Accesswire
- 4 days ago - Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts - Accesswire
- 4 days ago - Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules - Accesswire
- 12 days ago - Jaguar Health, Inc. Announces Reverse Stock Split - Accesswire
- 17 days ago - Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders - Accesswire
- 4 weeks ago - Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value - Accesswire
- 5 weeks ago - Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF) - Accesswire